What Is Colorectal Cancer? 

Colorectal cancer (CRC) is the third most diagnosed cancer, accounting for about 10% of cancers. It’s also the second leading cause of cancer deaths globally (1). As the role of targeted therapy in CRC is evolving, guidelines have expanded their recommendations regarding biomarker testing. Currently, detection of various gene alterations, such as KRAS, NRAS and BRAF mutations, HER2 amplifications, microsatellite instability (MSI), and mismatch repair deficient (MMR) status are recommended (2). As such, Cerba Research can provide a wide range of specialty and safety testing to your existing central laboratory CRC processes. Contact us to learn more.

Cerba Research Colorectal Cancer Services

Our CRC specialists support a wide range of colorectal studies from preclinical (data not shown) to phase III registration trials and beyond. Most of our projects include specialty testing, such as, but not limited to, NGS broad-panel assays, ctDNA panels, 250+ IHC simplex and multiplex protocols, and more. Get in touch to learn more. 

Our Areas Of Expertise In Colorectal Cancer 

Did you know that we can cover for your CRC biomarker needs? Check out our mapping exercise by select CRC biomarkers against our Cerba Research offerings with three techniques (NGS, IHC, FISH). Check out our resources below.

CEA=carcinoembryonic antigen determination; dMMR= mismatch repair deficient; FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; MSI=microsatellite instability; NGS=next-generation sequencing; TMB=tumor mutation burden.

References

1. World Health Organization: Colorectal cancer. URL [https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer].  

2. National Comprehensive Cancer Network®: NCCN guidelines, treatment by cancer type. URL [Treatment by Cancer Type (nccn.org)].

3. Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol. 2021 Jan 15;28(1):523-548. doi: 10.3390/curroncol28010053. PMID: 33467570; PMCID: PMC7903287.